Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Matthew D Ettleson"'
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Clinical hypothyroidism is defined by the inadequate production of thyroid hormone from the thyroid gland to maintain normal organ system functions. For nearly all patients with clinical hypothyroidism, lifelong treatment with thyroid hormone replace
Externí odkaz:
https://doaj.org/article/43a3291c18b24408bb584df62922ffc7
Publikováno v:
The Lancet Diabetes & Endocrinology. 10:366-372
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab71b5ab521349cc99bfe3fb1077091f
https://doi.org/10.1016/s2213-8587(22)00004-3
https://doi.org/10.1016/s2213-8587(22)00004-3
Publikováno v:
J Clin Endocrinol Metab
Context Many patients with hypothyroidism receive suboptimal treatment that may affect hospital outcomes. Objective This work aimed to identify differences in hospital outcomes between patients with and without hypothyroidism. Methods A retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e0b445122c179c0e225332b70cf04a
https://doi.org/10.1210/clinem/dgac215
https://doi.org/10.1210/clinem/dgac215
Autor:
Matthew D. Ettleson, Ava Raine, Alice Batistuzzo, Samuel P. Batista, Elizabeth McAninch, Maria Cristina T.V. Teixeira, Jacqueline Jonklaas, Neda Laiteerapong, Miriam O. Ribeiro, Antonio C. Bianco
Publikováno v:
Endocr Pract
OBJECTIVE: Patient-centered studies have shown that several patients on thyroid hormone replacement therapy for hypothyroidism exhibit persistent symptoms, including “brain fog.” Here, we aimed to determine which of these specific symptoms are as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce8ba16eab47a389245a4d1740af770c
https://doi.org/10.1016/j.eprac.2021.12.003
https://doi.org/10.1016/j.eprac.2021.12.003
Autor:
Erin C. Hanlon, Matthew D Ettleson, Alexandra M. Dumitrescu, Marilyn Arosemena, Antonio C. Bianco, Mihai Giurcanu, Olga Duchon
Publikováno v:
Thyroid
Background: L-triiodothyronine (LT3) has been increasingly used in combination with levothyroxine in the treatment of hypothyroidism. A metal coordinated form of LT3, known as poly-zinc-liothyronine (PZL), avoided in rats the typical triiodothyronine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b88b77574fabc39221d5ba5e61376a9
https://doi.org/10.1089/thy.2021.0304
https://doi.org/10.1089/thy.2021.0304
Autor:
Matthew D Ettleson, Wesley H Prieto, Pedro S T Russo, Jose de Sa, Wen Wan, Neda Laiteerapong, Rui M B Maciel, Antonio C Bianco
Publikováno v:
The Journal of clinical endocrinology and metabolism.
Context Small adjustments in levothyroxine (LT4) dose do not appear to provide clinical benefit despite changes in thyrotropin (TSH) levels within the reference range. We hypothesize that the accompanying changes in serum total triiodothyronine (T3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da699a620a031a6b8be38b9b3d73ca0
https://pubmed.ncbi.nlm.nih.gov/36515655
https://pubmed.ncbi.nlm.nih.gov/36515655
Publikováno v:
Lancet Diabetes Endocrinol
Levothyroxine monotherapy has been the standard of care for treatment of hypothyroidism for more than 40 years. However, patients treated with levothyroxine have relatively lower serum tri-iodothyronine (T(3)) concentrations than the general populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab24adc5e6504ecff327b08112f3afce
https://pubmed.ncbi.nlm.nih.gov/35240052
https://pubmed.ncbi.nlm.nih.gov/35240052
Autor:
Erin C. Hanlon, Duchon O, Bianco A, Arosema M, Mihai Giurcanu, Alexandra M. Dumitrescu, Matthew D Ettleson
BackgroundLiothyronine (LT3) has been increasingly used in combination with levothyroxine (LT4) in the treatment of hypothyroidism. A metal coordinated form of LT3, known as poly-zinc-liothyronine (PZL), avoided in rats the typical T3 peak seen after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b28b1f2032f40723f50e014181453653
https://doi.org/10.1101/2021.06.14.21258437
https://doi.org/10.1101/2021.06.14.21258437
Publikováno v:
Journal of the Endocrine Society
Purpose Both undertreatment and overtreatment of hypothyroidism with thyroid hormone are associated with adverse clinical outcomes. Disparities in the treatment of hypothyroidism may lead to a higher risk of adverse outcomes for certain sociodemograp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::667dadb4a64a07ef8dafe49394043d0c
https://doi.org/10.1210/jendso/bvab041
https://doi.org/10.1210/jendso/bvab041
Autor:
Julie K. Johnson, Wesley H. Prieto, Antonio C. Bianco, Matthew D Ettleson, Flavia A Andreotti Narchi, Sabina Casula, Aswathy Ajith, Anoop Mayampurath, Thaer Idrees, Rui M. B. Maciel, Pedro de Sá Tavares Russo, Fernando Fernandes
Publikováno v:
Journal of the Endocrine Society
Context Treatment with levothyroxine (LT4) that normalize serum thyrotropin (TSH) is expected to restore lipid metabolism. Objective To assess statin utilization in LT4-treated patients through an observational drug utilization study. Methods Three s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90bad7f9efeeefc72a13e4f6a9be86f1
https://doi.org/10.1210/jendso/bvab038
https://doi.org/10.1210/jendso/bvab038